Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

White House names Weems acting CMS administrator

Executive Summary

The White House names Kerry Weems acting CMS administrator Sept. 4. In a prepared statement, HHS Secretary Mike Leavitt said Weems "understands the large fiscal challenges facing Medicare and Medicaid and what it will take to strengthen and sustain those programs for the future." The Senate Finance Committee held a confirmation hearing July 25 that appeared to present no significant hurdles in the confirmation process, but the committee has not yet held a vote to move the nomination to the full Chamber for confirmation (1"The Pink Sheet" July 30, 2007, p. 27). HHS also formalized Herb Kuhn's role as deputy administrator of CMS...

You may also be interested in...



Part D Generic Dispensing Rates Among Upcoming Plan Performance Metrics

Medicare Part D plan performance measures will be posted to the CMS Web site on Nov. 15

Senate Finance Committee Is Not SquWeemish About CMS Nominee

CMS Administrator-Nominee Kerry Weems faced no serious challenges during a July 25 confirmation hearing held by the Senate Finance Committee, with most of his comments focusing on a pledge to emphasize oversight of CMS programs

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel